Nectar Lifesciences Intrinsic Value
Nectar Lifesciences (NECLIFE) median intrinsic value is ₹31.02 from 2 valuation models (range ₹31–₹31), vs current price ₹12.41 — +150.0% upside (Trading Below Calculated Value), margin of safety 60.0%. For current market price and key ratios, visit NECLIFE company profile.
NECLIFE Valuation Methods Summary — DCF, Graham Number & P/E
Nectar Lifesciences intrinsic value across 2 models vs current price ₹12.41 — upside/downside and value range per method. Also explore Nectar Lifesciences share price performance to track price trends across different timeframes.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹31.02 | ₹27.92 - ₹34.12 | +150.0% | Book Value/Share: ₹434.55, P/B: 2.0x |
| Simple DCF (5Y) | dcf | ₹31.02 | ₹24.82 - ₹37.22 | +150.0% | CF Growth: 15.0%, Discount: 15% |
NECLIFE Intrinsic Value vs Market Price — All Valuation Models
Nectar Lifesciences fair value range ₹31–₹31 vs current market price ₹12.41 across 2 valuation models. Read NECLIFE ex-dividend dates for the complete payout history and dividend yield track record.
NECLIFE Intrinsic Value Analysis — Undervalued or Overvalued?
Nectar Lifesciences median intrinsic value ₹31.02, current price ₹12.41 — Trading Below Calculated Value by 150.0%, margin of safety 60.0%.
What is the intrinsic value of NECLIFE?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Nectar Lifesciences (NECLIFE) is ₹31.02 (median value). With the current market price of ₹12.41, this represents a +150.0% variance from our estimated fair value.
The valuation range spans from ₹31.02 to ₹31.02, indicating ₹31.02 - ₹31.02.
Is NECLIFE undervalued or overvalued?
Based on our multi-method analysis, Nectar Lifesciences (NECLIFE) appears to be trading below calculated value by approximately 150.0%.
NECLIFE Financial Health — Key Ratios vs Industry Benchmarks
Nectar Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 17.69 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -73.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
NECLIFE Cash Flow Quality — Operating & Free Cash Flow
Nectar Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹169 Cr | ₹148 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹225 Cr | ₹217 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹134 Cr | ₹134 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹95 Cr | ₹95 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹21 Cr | ₹7 Cr | Positive Free Cash Flow | 7/10 |